Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
16th Nov 2006, 08:21 GMT
Critical Therapeutics announced the presentation of 3 posters at the American College of Allergy, Asthma and Immunology 2006 Annual Meeting in Philadelphia.
Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting related news:
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data — EurekAlert! - Medicine and Health
- Data on PolyMedix's Novel Antibiotics Presented at the 40th Annual Meeting of the Ocular Microbiology and Immunology Group — Pharmaceuticals News from StratCenter.com
- Oxford Biomedica Presents Encouraging Preclinical Efficacy Data With Prosavin® In Parkinson's Disease — Health News from Medical News Today
- Complementary Medicine Has A Role In The Treatment Of Allergic Diseases — Health News from Medical News Today
- ORENCIA Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria — StratWire - Business of Healthcare NewsFeed
- New Data On Otsuka's Investigational Product For Hyponatremia Presented At American Heart Association Annual Meeting — Health News from Medical News Today
- 12 Studies Evaluating Cytyc's MammoSite Radiation Therapy System Presented at ASTRO Annual Meeting — Nuclear Medicine News from StratCenter.com
- Alba Therapeutics Presents Data From Positive Phase Ib Clinical Trial At The XII International Celiac Disease Symposium — Health News from Medical News Today
- Embraer Announces Third Quarter 2006 Results in US GAAP The Company's operating and financial information is presented, except where otherwise stated, on a consolidated basis in United States dollars (US$) in accordance with US GAAP. The financial data presented in this document for the quarters ended September 30, 2006, June 30, 2006 and September 30, 2005 are derived from our unaudited financial statements. In order to better understand the Company's operating performance, we also present at the end of this release certain information in accordance with the Brazilian Corporate Law ("Brazilian GAAP"). — mysan.de - Lifestyle News
- New Survey Data Reveal Majority of Asthma Patients Remain Uncontrolled Based on Scores from the Asthma Control Test — Physician News News from StratCenter.com
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- FermaVir's Founder and Board Member Professor Chris McGuigan receives the Royal Society of Chemistry's Award for Medicinal Chemistry